Bernhardt Zeiher Buys 5,000 Shares of Entrada Therapeutics (NASDAQ:TRDA) Stock

Entrada Therapeutics, Inc. (NASDAQ:TRDA) Director Bernhardt Zeiher bought 5,000 shares of the stock in a transaction on Wednesday, May 20th. The stock was purchased at an average price of $5.86 per share, with a total value of $29,300.00. Following the completion of the purchase, the director owned 5,000 shares of the company’s stock, valued at $29,300. This represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through this link.

Entrada Therapeutics Stock Up 4.0%

Shares of TRDA opened at $6.56 on Friday. The company has a market cap of $254.66 million, a price-to-earnings ratio of -1.64 and a beta of -0.09. Entrada Therapeutics, Inc. has a twelve month low of $4.93 and a twelve month high of $16.45. The company has a 50 day moving average of $11.53 and a two-hundred day moving average of $10.85.

Entrada Therapeutics (NASDAQ:TRDA) last announced its earnings results on Thursday, May 7th. The company reported ($0.95) earnings per share for the quarter, beating the consensus estimate of ($1.06) by $0.11. The company had revenue of $0.88 million during the quarter, compared to the consensus estimate of $2.92 million. Entrada Therapeutics had a negative net margin of 2,895.05% and a negative return on equity of 51.22%. On average, sell-side analysts expect that Entrada Therapeutics, Inc. will post -4.12 EPS for the current year.

Analysts Set New Price Targets

TRDA has been the subject of several research reports. Guggenheim upgraded shares of Entrada Therapeutics to a “strong-buy” rating in a research note on Wednesday, February 11th. Cantor Fitzgerald assumed coverage on shares of Entrada Therapeutics in a research report on Wednesday, April 1st. They set an “overweight” rating for the company. Wall Street Zen downgraded shares of Entrada Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, March 28th. HC Wainwright downgraded shares of Entrada Therapeutics from a “buy” rating to a “neutral” rating in a research report on Friday, May 8th. Finally, Oppenheimer boosted their target price on shares of Entrada Therapeutics from $21.00 to $23.00 and gave the company an “outperform” rating in a research report on Monday, April 6th. One equities research analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $18.25.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in TRDA. Baker BROS. Advisors LP increased its stake in shares of Entrada Therapeutics by 4.3% during the fourth quarter. Baker BROS. Advisors LP now owns 5,072,730 shares of the company’s stock worth $52,148,000 after purchasing an additional 206,911 shares in the last quarter. Wellington Management Group LLP increased its stake in shares of Entrada Therapeutics by 9.5% during the fourth quarter. Wellington Management Group LLP now owns 1,044,758 shares of the company’s stock worth $10,740,000 after purchasing an additional 90,339 shares in the last quarter. Millennium Management LLC increased its stake in shares of Entrada Therapeutics by 391.2% during the third quarter. Millennium Management LLC now owns 836,609 shares of the company’s stock worth $4,852,000 after purchasing an additional 666,287 shares in the last quarter. Geode Capital Management LLC increased its stake in shares of Entrada Therapeutics by 7.2% during the second quarter. Geode Capital Management LLC now owns 631,554 shares of the company’s stock worth $4,245,000 after purchasing an additional 42,479 shares in the last quarter. Finally, State Street Corp increased its stake in shares of Entrada Therapeutics by 2.0% during the fourth quarter. State Street Corp now owns 508,789 shares of the company’s stock worth $5,230,000 after purchasing an additional 10,174 shares in the last quarter. Hedge funds and other institutional investors own 86.39% of the company’s stock.

About Entrada Therapeutics

Entrada Therapeutics (NASDAQ: TRDA) is a clinical-stage biotechnology company focused on enabling the development of protein-based therapeutics that can cross cell membranes and engage intracellular targets. Using its proprietary cell-penetrating miniature protein (CPMP) platform and intracellular targeting of proteins (iTOP) delivery technology, Entrada aims to expand the range of diseases addressable by large-molecule drugs.

The company’s pipeline includes programs in rare and serious diseases where conventional biologics have limited intracellular activity.